Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment

Journal of Hepatology

Volumn 63, Issue 4, 2015, Pages 805-812

  Khatri, Amit ^a   Menon, Rajeev M ^a   Marbury, Thomas C ^b   Lawitz, Eric J ^c   Podsadecki, Thomas J ^a   Mullally, Victoria M ^a   Ding, Bifeng ^a   Awni, Walid M ^a   Bernstein, Barry M ^a   Dutta, Sandeep ^a  

^a ABBVIE INC   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Chronic hepatitis C; Dasabuvir; Direct acting antiviral agents; Hepatic impairment; Ombitasvir; Paritaprevir; Pharmacokinetics; Ritonavir

Indexed keywords

DASABUVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; CYTOCHROME P450 3A INHIBITOR; MACROCYCLIC COMPOUND; RIBAVIRIN; SULFONAMIDE; URACIL;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INJECTION SITE PAIN; INSOMNIA; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; MULTICENTER STUDY; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SEVERE HEPATIC IMPAIRMENT; SINGLE DRUG DOSE; UNBOUND FRACTION; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; HEPATIC INSUFFICIENCY; HEPATITIS C, CHRONIC; LIVER FUNCTION TEST; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; CYTOCHROME P-450 CYP3A INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATIC INSUFFICIENCY; HEPATITIS C, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RIBAVIRIN; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; URACIL;

EID: 84941933839     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.05.029     Document Type: Article

References (27)

1. World Health Organization (WHO) Hepatitis C Wkly Epidemiol Rec 86 2011 445 447
2. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002 Hepatology 36 2002 S3 S20
3. J.M. Pawlotsky Pathophysiology of hepatitis C virus infection and related liver disease Trends Microbiol 12 2004 96 102
4. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, D. Crawford, and et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
5. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, K. Agarwal, and et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
6. R. Menon, M. Kapoor, E. Dumas, P. Badri, A. Campbell, P. Gulati, and et al. Multiple-dose pharmacokinetics and safety following coadministration of ABT-450/r, ABT-267, and ABT-333 in Caucasian, Japanese, and Chinese Subjects [abstract 1497] Hepatol Int 7 2013 400
7. C.G. Child, and J.G. Turcotte Surgery and portal hypertension C.G. Child III The liver and portal hypertension 1964 WB Saunders Philadelphia, PA 50 64
8. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, and R. Williams Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
9. M.R. Lucey, K.A. Brown, G.T. Everson, J.J. Fung, R. Gish, E.B. Keeffe, and et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases Liver Transpl Surg 3 1997 628 637
10. K.V. Kowdley, E. Lawitz, F. Poordad, D.E. Cohen, D.R. Nelson, S. Zeuzem, and et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 N Engl J Med 370 2014 222 232
11. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, S. Siggelkow, and et al. Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
12. G.J. Sullivan, M. Rodriques-Torres, E. Lawitz, F. Poordad, M. Kapoor, A. Campbell, and et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis [abstract 1210] J Hepatol 56 2012 S480
13. G. Zollner, P. Fickert, D. Silbert, A. Fuchsbichler, H.U. Marschall, K. Zatloukal, and et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis J Hepatol 38 2003 717 727
14. V.R. More, Q. Cheng, A.C. Donepudi, D.B. Buckley, Z.J. Lu, N.J. Cherrington, and et al. Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver Drug Metab Dispos 41 2013 1148 1155
15. M. Bifano, H. Sevinsky, A. Persson, E. Chung, M. Wind-Rotolo, C. Hwang, and et al. Single-dose pharmacokinetics of BMS-790052 in subjects with hepatic impairment compared with healthy subjects [abstract 1362] Hepatology 54 2011 1004A
16. E. Mogalian, A. Mathias, D. Brainard, J. McNally, L. Moorehead, M. Hernandez, and et al. The pharmacokinetics of GS-5816, a pan-genotypic HCV NS5A inhibitor, in HCV-uninfected subjects with moderate and severe hepatic impairment [abstract P742] J Hepatol 60 2014 S317
17. Bertz R. Bristol-Myers Squibb HCV full development portfolio overview. In: 14th international workshop on clinical pharmacology of HIV therapy, session 5, < http://regist2.virology-education.com/2013/14hivpk/docs/27-Bertz.pdf >; 2013 [accessed August 18, 2014].
18. Mogalian E, German P, Yang C, Moorehead L, Brainard D, McNally J, et al. Evaluation of transporter and cytochrome P450-mediated drug-drug interactions between pan-genotypic HCV NS5A inhibitor GS-5816 and phenotypic probe drugs. In: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy, May 19-21, 2014, Washington, DC, < http://regist2.virology-education.com/2014/15HIVHEP-PK/11-Mogalian.pdf > [accessed August 18, 2014].
19. T. Eley, B. He, I. Chang, E. Colston, M. Child, W. Bedford, and et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor Antivir Ther 2014 10.3851/IMP2773 [Epub ahead of print]
20. V. Sekar, A. Simion, M. Peeters, K. Spittaels, E. Lawitz, T.C. Marbury, and et al. Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment [abstract 472] J Hepatol 54 2011 S193
21. T. Eley, Y. Han, S. Huang, B. He, W. Li, W. Bedford, and et al. In vivo and in vitro assessment of asunaprevir as an inhibitor and substrate of OATP transporters in healthy volunteers [abstract PK-04] Rev Antivir Ther Infect Dis 6 2012 7
22. Olysio™ (simeprevir) [US package insert]. Titusville, NJ; Janssen Therapeutics, November 2013. < http://www.olysio.com/shared/product/olysio/prescribing-information.pdf > [accessed August 18, 2014].
23. T.N. Johnson, K. Boussery, K. Rowland-Yeo, G.T. Tucker, and A. Rostami-Hodjegan A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance Clin Pharmacokinet 49 2010 189 206
24. J. George, M. Murray, K. Byth, and G.C. Farrell Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease Hepatology 21 1995 120 128
25. D. Lucas, F. Berthou, Y. Dréano, P. Lozac'h, A. Volant, and J.F. Ménez Comparison of levels of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples Alcohol Clin Exp Res 17 1993 900 905
26. Norvir® (ritonavir) [US package insert]. North Chicago, IL; AbbVie Inc., November 2013. < http://www.rxabbvie.com/pdf/norvirtab-pi.pdf > [accessed August 18, 2014].
27. R.F. Frye, N.K. Zgheib, G.R. Matzke, D. Chaves-Gnecco, M. Rabinovitz, O.S. Shaikh, and et al. Liver disease selectively modulates cytochrome P450-mediated metabolism Clin Pharmacol Ther 80 2006 235 245